PRE DIAGNOSTICS AS

Their core work

Pre Diagnostics is a Norwegian SME focused on early detection of neurodegenerative diseases, particularly Alzheimer's disease. They develop blood-based biomarker diagnostics and digital screening tools for dementia risk assessment. Their work bridges wet-lab diagnostics (blood tests identifying Alzheimer's pathology) with AI-powered brain connectivity analysis, positioning them at the intersection of clinical diagnostics and digital health. They coordinate clinical validation projects and contribute diagnostic expertise to larger research consortia.

What they specialise in

How they've shifted over time

Pre Diagnostics entered H2020 in 2019 with parallel efforts in both biological research (SAND — autophagy and neurodegeneration mechanisms) and applied diagnostics (VERDAD — blood biomarkers for Alzheimer's). By 2021, their focus shifted decisively toward digital and AI-based approaches with AI-Mind, incorporating machine learning, deep learning, and multimodal risk assessment for dementia screening. This trajectory shows a clear move from bench-level biology toward scalable, technology-driven diagnostic tools.

Pre Diagnostics is moving from laboratory biomarker research toward AI-enabled, scalable digital screening tools for neurodegenerative diseases — a direction aligned with growing demand for non-invasive, early-stage dementia detection.

How they like to work

Pre Diagnostics operates as both a project leader and a contributing specialist. They coordinated VERDAD (their largest project at EUR 2.36M under the SME Instrument), showing capacity to lead clinical validation efforts, while also joining larger research consortia like SAND and AI-Mind as a participant. With 35 unique partners across 14 countries from just 3 projects, they are comfortable in broad, international consortia rather than small, tight-knit teams.

Despite only three H2020 projects, Pre Diagnostics has built a wide network of 35 partners across 14 countries, reflecting their participation in large multi-national health consortia. Their reach is distinctly pan-European rather than concentrated in any single region.

What sets them apart

Pre Diagnostics combines two capabilities that rarely sit in the same SME: deep understanding of neurodegenerative disease biology (protein secretion, autophagy pathways) and applied AI/digital health tool development for clinical screening. This dual competence makes them a valuable bridge between fundamental neuroscience research and market-ready diagnostic products. Their SME Instrument funding for VERDAD signals that the EU recognized their commercial readiness, not just their research quality.

Highlights from their portfolio

• VERDAD
  Their flagship project as coordinator (EUR 2.36M, SME Instrument Phase 2), validating a blood-based biomarker for early Alzheimer's detection — a high-commercial-potential diagnostic.
• AI-Mind
  A large-scale health RIA running until 2026 that applies deep learning and brain connectivity analysis to dementia screening, representing their strategic pivot toward AI-powered diagnostics.